Response to: GCP III is not the "off-target" for urea-based PSMA-ligands
Eur J Nucl Med Mol Imaging
.
2023 Aug;50(10):2947-2949.
doi: 10.1007/s00259-023-06302-4.
Epub 2023 Jun 21.
Authors
Gabriele Bassi
#
1
,
Samuele Cazzamalli
#
2
,
Sebastian Oehler
3
,
Laura Lucaroni
3
,
Tony Georgiev
3
,
Nicholas Favalli
3
,
Dario Neri
4
Affiliations
1
Small Molecule Therapeutics Department, Philochem AG, Libernstrasse 3, 8112, Otelfingen, Switzerland. gabriele.bassi@philochem.ch.
2
Small Molecule Therapeutics Department, Philochem AG, Libernstrasse 3, 8112, Otelfingen, Switzerland. samuele.cazzamalli@philochem.ch.
3
Small Molecule Therapeutics Department, Philochem AG, Libernstrasse 3, 8112, Otelfingen, Switzerland.
4
Small Molecule Therapeutics Department, Philochem AG, Libernstrasse 3, 8112, Otelfingen, Switzerland. dario.neri@philogen.com.
#
Contributed equally.
PMID:
37341746
DOI:
10.1007/s00259-023-06302-4
No abstract available
Publication types
Letter
Comment
MeSH terms
Antigens, Surface
Cell Line, Tumor
Glutamate Carboxypeptidase II*
Humans
Ligands
Urea*
Substances
Ligands
Urea
Glutamate Carboxypeptidase II
Antigens, Surface